Dana Investment Advisors Inc. trimmed its position in BioTelemetry, Inc. (NASDAQ:BEAT) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,072 shares of the medical research company’s stock after selling 3,621 shares during the quarter. Dana Investment Advisors Inc. owned about 0.25% of BioTelemetry worth $2,745,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Great West Life Assurance Co. Can raised its position in BioTelemetry by 3.2% during the first quarter. Great West Life Assurance Co. Can now owns 39,099 shares of the medical research company’s stock valued at $1,130,000 after acquiring an additional 1,227 shares in the last quarter. Bank of New York Mellon Corp raised its position in BioTelemetry by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 526,725 shares of the medical research company’s stock valued at $15,249,000 after acquiring an additional 24,601 shares in the last quarter. Comerica Bank raised its position in BioTelemetry by 5.3% during the first quarter. Comerica Bank now owns 31,371 shares of the medical research company’s stock valued at $1,018,000 after acquiring an additional 1,568 shares in the last quarter. Ameriprise Financial Inc. raised its position in BioTelemetry by 1.5% during the first quarter. Ameriprise Financial Inc. now owns 206,649 shares of the medical research company’s stock valued at $5,983,000 after acquiring an additional 3,115 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in BioTelemetry by 35.2% during the first quarter. Parametric Portfolio Associates LLC now owns 89,484 shares of the medical research company’s stock valued at $2,591,000 after acquiring an additional 23,312 shares in the last quarter. Hedge funds and other institutional investors own 77.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “BioTelemetry, Inc. (BEAT) Shares Sold by Dana Investment Advisors Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/biotelemetry-inc-beat-shares-sold-by-dana-investment-advisors-inc/1615543.html.

Shares of BioTelemetry, Inc. (BEAT) traded down 1.34% during mid-day trading on Friday, reaching $33.20. The company’s stock had a trading volume of 275,555 shares. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 22.28 and a beta of 0.68. BioTelemetry, Inc. has a 1-year low of $15.25 and a 1-year high of $39.20. The company’s 50 day moving average price is $34.86 and its 200-day moving average price is $31.99.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The business had revenue of $58.10 million during the quarter, compared to the consensus estimate of $58.39 million. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.20 EPS. Analysts predict that BioTelemetry, Inc. will post $0.99 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the company. Off Wall Street assumed coverage on BioTelemetry in a research report on Friday, September 15th. They set a “sell” rating for the company. BidaskClub upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. Dougherty & Co lifted their price target on BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Benchmark Co. lifted their price target on BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price target for the company in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company. BioTelemetry currently has a consensus rating of “Buy” and an average target price of $44.40.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.